Literature DB >> 12037396

Epicutaneous application of protein antigens incorporated into cosmetic cream induces antigen-nonspecific unresponsiveness in mice and affects the cell-mediated immune response.

Włodzimierz Ptak1, Marian Szczepanik, Krysztof Bryniarski, Monika Tutaj, Maria Ptak.   

Abstract

BACKGROUND: Protein antigens applied epicutaneously by the patch method induce allergic dermatitis mediated by IgE antibodies in mice and simultaneously significant suppression of Th1-mediated delayed-type hypersensitivity (DTH) reactions.
METHODS: We developed a method in which protein antigens (calf collagen, elastin, keratin, TNP-substituted mouse Ig) were homogenized with neutral cream. Animals treated epicutaneously with such preparations were tested for contact sensitivity to TNP hapten or DTH hypersensitivity to hemocyanin. Antigen specificity of induced unresponsiveness was tested in vivo in 'transfer-in' and 'transfer-out' experiments. The influence of skin-induced regulatory cells on in vitro [3H]thymidine uptake by immune cells as well as the possible mode of their action using anticytokine antibodies were tested.
RESULTS: Our procedure in which different protein antigens are applied on the skin in the form of cream induces a state of antigen-nonspecific unresponsiveness affecting cell-mediated immune responses in mice. Cream alone has no such effect. Suppression is transferable in vivo by TCR-alphabeta lymphocytes, while Tgammadelta cells show no activity. In vitro, lymphoid cells of skin-tolerized mice suppress [3H]-thymidine incorporation by immune cells and this effect can be abolished by adding anti-TGF-beta but neither anti-IL-4 nor anti-IL-10 antibodies.
CONCLUSIONS: Lack of antigen-specifity of unresponsiveness induced by epicutaneous deposition of cream containing protein antigens resembles 'determinant spreading' in oral tolerance induced by antigen feeding. This may suggest that similar immunoregulatory mechanisms operate on these two bodily surfaces. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12037396     DOI: 10.1159/000057998

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  6 in total

1.  Epicutaneous immunization induces alphabeta T-cell receptor CD4 CD8 double-positive non-specific suppressor T cells that inhibit contact sensitivity via transforming growth factor-beta.

Authors:  Marian Szczepanik; Krzysztof Bryniarski; Monika Tutaj; Maria Ptak; Joanna Skrzeczynska; Philip W Askenase; Wlodzimierz Ptak
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

Review 2.  Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis.

Authors:  Julia K Gittler; James G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2012-08-28       Impact factor: 10.793

3.  Macrophages play an essential role in antigen-specific immune suppression mediated by T CD8⁺ cell-derived exosomes.

Authors:  Katarzyna Nazimek; Wlodzimierz Ptak; Bernadeta Nowak; Maria Ptak; Philip W Askenase; Krzysztof Bryniarski
Journal:  Immunology       Date:  2015-04-27       Impact factor: 7.397

4.  Epicutaneous immunization with TNP-Ig and Zymosan induces TCRαβ+ CD4+ contrasuppressor cells that reverse skin-induced suppression via IL-17A.

Authors:  Monika Majewska-Szczepanik; Anna Strzepa; Katarzyna Marcińska; Li Wen; Marian Szczepanik
Journal:  Int Arch Allergy Immunol       Date:  2014-06-28       Impact factor: 2.749

5.  Epicutaneous immunization with ovalbumin and CpG induces TH1/TH17 cytokines, which regulate IgE and IgG2a production.

Authors:  Monika Majewska-Szczepanik; Philip W Askenase; Francis M Lobo; Katarzyna Marcińska; Li Wen; Marian Szczepanik
Journal:  J Allergy Clin Immunol       Date:  2016-01-22       Impact factor: 10.793

6.  Intradermal Delivery of Antigens Enhances Specific IgG and Diminishes IgE Production: Potential Use for Vaccination and Allergy Immunotherapy.

Authors:  Takuwa Yasuda; Takehiro Ura; Masaru Taniguchi; Hisahiro Yoshida
Journal:  PLoS One       Date:  2016-12-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.